Chimera Researc...'s  Instablog

Chimera Research Group
Send Message
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA).... More
My company:
Chimera Research Group
My blog:
Chimera Blog
My book:
The Biotech Trader Handbook (2nd Edition)
  • Idenix: Two Steps Forward and One Step Back 0 comments
    Feb 10, 2011 1:02 AM
    It has happened before- just when things were beginning to look up, Idenix has taken another beating. This time, the experimental AIDS drug it had licensed to ViiV Healthcare, an affiliate of GSK, had been placed on clinical hold by the FDA. The compound, IDX899, a non-nucleoside reverse-transcriptase inhibitor (NNRTI) had only begun Phase IIb clinical studies in November 2010. Shares fell 25% in after hours trading.
    IDX899 is one of Idenix’s key assets. It has already received $60 million in upfront and milestone payments through the ViiV deal and could potentially receive an additional $390 million along with double-digit royalties. These are now in doubt.
    There was some good news announced today as well; while one candidate was put on hold, a second one was changed from a full to partial hold. The FDA decided to allow trials to continue for Idenix’s lead HCV compound, IDX-184. It will move into Phase IIb in the second half of this year in a 12-week trial in combination with pegylated interferon and ribavarin.
    The initial hold occurred in September 2010 as a result of three cases of elevated liver function tests observed during a drug-drug interaction study of the combination of IDX184 and IDX320, an HCV protease inhibitor. At that time, the stock was cut in half. IDX320 has now been determined as the culprit in that study.
    Returning IDX-184 to the clinic should result in a net positive for the company; it is one of the few nucleotide inhibitors in development in a future where HCV treatment will be through a combination of pills with non-overlapping activity. Unattached, it also offers potential partnership opportunities for Idenix.
Back To Chimera Research Group's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • $CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs
    Nov 10, 2012
  • We are big believers in $PCYC, $MDVN, $INCY, $SGEN and more.
    Jul 10, 2012
  • $CHTP: 700 call contracts traded today. speculative interest returning...?
    Aug 10, 2010
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.